CY1108200T1 - Ιππειο εμβολιο ιου του ερπητα - Google Patents

Ιππειο εμβολιο ιου του ερπητα

Info

Publication number
CY1108200T1
CY1108200T1 CY20081100745T CY081100745T CY1108200T1 CY 1108200 T1 CY1108200 T1 CY 1108200T1 CY 20081100745 T CY20081100745 T CY 20081100745T CY 081100745 T CY081100745 T CY 081100745T CY 1108200 T1 CY1108200 T1 CY 1108200T1
Authority
CY
Cyprus
Prior art keywords
ehv
vaccine
inactivated
equine
herpes virus
Prior art date
Application number
CY20081100745T
Other languages
English (en)
Inventor
Mark W Mellencamp
Original Assignee
Boehringer Ingelheim Vetmedica, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica, Inc. filed Critical Boehringer Ingelheim Vetmedica, Inc.
Publication of CY1108200T1 publication Critical patent/CY1108200T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Ένα εμβόλιο για προστασία ενός αλόγου έναντι νόσων οι οποίες συνδέονται με EHV-1 και/ή EHV-4 παρέχεται. Το εμβόλιο κοινά περιλαμβάνει αδρανοποιημένο EHV-1 (π.χ. χημικά αδρανοποιημένο EHV-1 KyA ιό) και ένα ανοσοενισχυτικό. Το ανοσοενισχυτικό μπορεί να περιλαμβάνει ένα διασταυρούμενης-σύνδεσης πολυμερές ολεφινικά ακόρεστου καρβοξυλικού οξέος το οποίο μπορεί να έχει βιοπροσκολλητικές ιδιότητες. Το εμβόλιο μπορεί επίσης να περιλαμβάνει αντιγόνα έναντι άλλων ίππειων παθογόνων όπως αδρανοποιημένου EHV-4 και αδρανοποιημένων Α1 και/ή Α2 στελεχών του ίππειου ιού της γρίπης. Μέθοδοι για προστασία αλόγων έναντι νόσων οι οποίες συνδέονται με EHV-1 και/ή EHV-4 και μέθοδοι παραγωγής του ίππειου εμβολίου ιού του έρπητα παρέχονται επίσης.
CY20081100745T 2001-03-20 2008-07-17 Ιππειο εμβολιο ιου του ερπητα CY1108200T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/812,720 US6803041B2 (en) 2001-03-20 2001-03-20 Equine herpesvirus vaccine
EP02713437A EP1372712B1 (en) 2001-03-20 2002-01-23 Equine herpesvirus vaccine

Publications (1)

Publication Number Publication Date
CY1108200T1 true CY1108200T1 (el) 2014-02-12

Family

ID=25210428

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100745T CY1108200T1 (el) 2001-03-20 2008-07-17 Ιππειο εμβολιο ιου του ερπητα

Country Status (15)

Country Link
US (3) US6803041B2 (el)
EP (2) EP1923071B1 (el)
JP (2) JP4177112B2 (el)
KR (1) KR100840525B1 (el)
AR (2) AR032984A1 (el)
AT (1) ATE392903T1 (el)
CA (1) CA2441292C (el)
CY (1) CY1108200T1 (el)
DE (1) DE60226218T2 (el)
DK (2) DK1372712T3 (el)
ES (2) ES2428664T3 (el)
MX (1) MXPA03008287A (el)
NZ (1) NZ529012A (el)
PT (1) PT1372712E (el)
WO (1) WO2002074335A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
JP2005075752A (ja) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science 豚繁殖・呼吸障害症候群用ワクチン製剤
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
NZ567684A (en) * 2005-11-01 2011-06-30 Intervet Int Bv Prime boost vaccine for the protection of equines against equine influenza
CA2732035A1 (en) 2008-07-30 2010-02-04 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
ES2675771T3 (es) 2008-12-16 2018-07-12 Ology Bioservices, Inc. Producción de vacunas contra el virus de la gripe
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
PL2569007T3 (pl) * 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
EP2996719B1 (en) * 2013-05-14 2019-06-26 Zoetis Services LLC Novel vaccine compositions comprising immunostimulatory oligonucleotides
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
AU2022321826A1 (en) * 2021-08-06 2024-01-25 Intervet International B.V. Vaccine for equine herpesvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4110433A (en) 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
US4083958A (en) 1976-09-13 1978-04-11 The University Of Kentucky Research Foundation Inactivated equine rhinopneumonitis virus vaccine and use thereof
US4225582A (en) 1979-03-08 1980-09-30 The University Of Illinois Foundation Vaccine for equine rhinopneumonitis
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5084271B1 (en) 1984-09-11 1997-08-05 Univ Melbourne Vaccine for equine herpesvirus
US4758641A (en) 1987-02-24 1988-07-19 The B F Goodrich Company Polycarboxylic acids with small amount of residual monomer
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5221722A (en) 1988-11-28 1993-06-22 The B. F. Goodrich Company Crosslinked polyacrylic acid
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
US6025181A (en) * 1990-07-06 2000-02-15 University Court Of The University Of Glasgow Equine herpesvirus-4TK mutant
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
CA2088246A1 (en) 1990-08-01 1992-02-02 Dennis J. O'callaghan Gene encoding equine herpesvirus type i glycoprotein d, its gene product, antibodies and their uses
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
WO1993024528A1 (en) 1992-06-01 1993-12-09 The University Of Melbourne Equine herpesvirus glycoproteins
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
US6225111B1 (en) * 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
AUPN720195A0 (en) * 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
EP0966679B1 (de) * 1997-03-12 2004-04-28 MERCK PATENT GmbH Endstück für eine chromatographische säule
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
EP0978286A1 (en) 1998-08-07 2000-02-09 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine

Also Published As

Publication number Publication date
CA2441292C (en) 2012-03-20
ES2305220T3 (es) 2008-11-01
WO2002074335A3 (en) 2003-07-17
CA2441292A1 (en) 2002-09-26
EP1923071A1 (en) 2008-05-21
JP2004525923A (ja) 2004-08-26
MXPA03008287A (es) 2004-10-28
AR091235A2 (es) 2015-01-21
US7226604B2 (en) 2007-06-05
EP1372712A2 (en) 2004-01-02
US20070196390A1 (en) 2007-08-23
ATE392903T1 (de) 2008-05-15
ES2428664T3 (es) 2013-11-08
WO2002074335A2 (en) 2002-09-26
DE60226218T2 (de) 2009-05-28
JP2007197470A (ja) 2007-08-09
DK1372712T3 (da) 2008-08-04
US20030206924A1 (en) 2003-11-06
JP4668951B2 (ja) 2011-04-13
EP1923071B1 (en) 2013-06-19
DK1923071T3 (da) 2013-08-26
DE60226218D1 (de) 2008-06-05
PT1372712E (pt) 2008-05-29
KR100840525B1 (ko) 2008-06-24
JP4177112B2 (ja) 2008-11-05
EP1372712B1 (en) 2008-04-23
US6803041B2 (en) 2004-10-12
NZ529012A (en) 2005-08-26
KR20030085028A (ko) 2003-11-01
AR032984A1 (es) 2003-12-03
US20050084502A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
CY1108200T1 (el) Ιππειο εμβολιο ιου του ερπητα
ES2157522T3 (es) Cepas de vacunas europeas del virus del sindrome respiratorio reproductor porcino (prrsv).
DE60137345D1 (de) Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
JP2007197470A5 (el)
DE60126349D1 (de) Rekombinantes nukleoprotein von newcastle-krankheitsvirus als markierungsimpfstoff
NO20030524L (no) Vaksine mot vertscelleassosiert herpesvirus
ATE297218T1 (de) Impfstoff gegen mehrere fiv-subtypen
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
AR040601A1 (es) Mutantes ehv negativos de gm sin elementos heterologos
ES2063897T5 (es) Vacuna contra el virus del colera porcino y diagnostico.
ES2132330T3 (es) Vacuna para la proteccion de caballos frente a la infeccion por el virus del herpes equino.
DE69226980D1 (de) Rekombinanter Varicella-Zoster-Virus-Vektor
ATE234631T1 (de) Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
ATE350058T1 (de) Sich gegenseitig schützende herpesviruszusammensetzung und verfahren zur deren herstellung und verwendung
Esterhuysen The antigenic variation of foot-and-mouth disease viruses and its significance in the epidemiology of the disease in southern Africa.
BR0304750A (pt) Mutante de herpesvìrus bovino tipo 5, vacina dirigida contra a encefalite viral bovina (bhv-s) e o vìrus rábico e método de preparação da vacina
WO2002020041A3 (en) Eia vaccine and diagnostic
HUP0202738A2 (hu) Ló herpeszvírus hőérzékeny mutánsa és az abból készített élő oltóanyag
BRPI0409430A (pt) processo para preparar sistemas catalisadores, sistema catalisador, processo para polimerizar ou copolimerizar olefinas, e, uso de um sistema catalisador
BRPI0409421A (pt) processo para preparar sistemas catalisadores, sistema catalisador, processo para polimerizar ou copolimerizar olefinas, e uso de um sistema catalisador
TH14736A (th) วัคซีนชนิดใหม่ของโรคติดเชื้อของเบอร์ซา (ibd) และสายพันธุ์ไวรัสโรคติดเชื้อของเบอร์ชาที่ทำให้อ่อนฤทธิ์ชนิดใหม่
TH18188A (th) วัคซีนสำหรับป้องกันโรคทางเดินหายใจและช่องทางสืบพันธ์ของสุกร
TH18188B (th) วัคซีนสำหรับป้องกันโรคทางเดินหายใจและช่องทางสืบพันธ์ของสุกร